Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Clinical trial NCT04538378 · TERMINATED
Trial details
- NCT number
- NCT04538378
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-07
- Primary completion
- 2023-03-22
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.